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One  of  the  hallmarks  of malignant  cell  populations  is  the  ability  to  undergo  continuous  proliferation.  This
property  allows  clonal  lineages  to  acquire  sequential  aberrations  that  can fuel  increasingly  autonomous
growth,  invasiveness,  and  therapeutic  resistance.  Innate  cellular  mechanisms  have  evolved  to regulate
replicative  potential  as  a  hedge  against  malignant  progression.  When  activated  in  the  absence  of  normal
terminal  differentiation  cues,  these  mechanisms  can  result  in a state  of persistent  cytostasis.  This state,ncogenic stress
termed  “senescence,”  can  be triggered  by  intrinsic  cellular  processes  such  as  telomere  dysfunction  and53
RB
oncogene  expression,  and  by exogenous  factors  such  as DNA  damaging  agents  or oxidative  environments.
Despite  differences  in  upstream  signaling,  senescence  often  involves  convergent  interdependent  activa-
tion  of tumor  suppressors  p53  and  p16/pRB,  but  can  be  induced,  albeit  with  reduced  sensitivity,  when
these  suppressors  are  compromised.  Doses  of  conventional  genotoxic  drugs  required  to achieve  cancer
cell senescence  are  often  much  lower  than  doses  required  to achieve  outright  cell  death.  Additional  thera-
pies, such  as those  targeting  cyclin  dependent  kinases  or components  of  the PI3K  signaling  pathway,  may
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induce  senescence  speciﬁcally  in  cancer  cells  by  circumventing  defects  in  tumor  suppressor  pathways
or exploiting  cancer  cells’  heightened  requirements  for  telomerase.  Such  treatments  sufﬁcient  to induce
cancer  cell  senescence  could  provide  increased  patient  survival  with  fewer  and less  severe  side  effects
than  conventional  cytotoxic  regimens.  This  positive  aspect  is  countered  by important  caveats  regarding
senescence  reversibility,  genomic  instability,  and  paracrine  effects  that  may  increase  heterogeneity  and
adaptive  resistance  of  surviving  cancer  cells.  Nevertheless,  agents  that  effectively  disrupt  replicative
immortality  will  likely  be valuable  components  of  new  combinatorial  approaches  to  cancer  therapy.
ublis
1
t
a
h
O
s
c
i
c
t
d
t
A
s
i
h
w
s
e
t
i
o
t
f
n
s
i
t
s
t
2
s
s
d
o
p
f
u
a
s
b
s
e
f
I
e
s
i
a
o©  2015  The  Authors.  P
. Introduction
Among the notable feats of evolution is the remarkable pro-
ection from cancer that is enjoyed by long-lived species such
s humans. Despite billions of cell divisions and trillions of cells,
umans remain, on average, cancer-free for more than 50 years.
ne of nature’s notable tumor suppressive mechanisms is cellular
enescence, a response to nonlethal stress that results in persistent
ytostasis. In the absence of normal growth arrest accompany-
ng differentiation, senescence imposes limits on the proliferative
apacity of clonal cell lineages. Senescence can be induced by mul-
iple stimuli, including intrinsic cellular processes such as telomere
ysfunction and oncogene expression, but also by exogenous fac-
ors such as DNA damaging agents or oxidative environments.
bundant published evidence now supports the concept that
enescence is a signiﬁcant impediment to malignancy, and that it
s ordinarily very stringent. Indeed, as a number of investigations
ave shown, many cell types in which one or more senescence path-
ay components are functionally inactivated remain susceptible to
enescence – an indication that robust compensatory mechanisms
xist for this important stress response. Despite the resiliency of
he senescence response, however, it is prone to failure to vary-
ng degrees, depending upon genetic/epigenetic context. Failure
f senescence in cells that have undergone oncogene activation,
elomere dysfunction, and/or DNA damage can result in changes
avoring malignancy and drug resistance. Elucidation of mecha-
isms that enforce senescence has been sought in expectation that
uch knowledge should lead to measures that prevent or reverse
ts failure in susceptible pre-malignant and malignant cell popula-
ions. In this review, we focus on telomeres and other mediators of
enescence induction as candidate targets for the prevention and
reatment of cancers.
. Causes of senescence
Proliferating cells can respond to genotoxic and non-genotoxic
tresses in a number of ways, including transient cell-cycle arrest,
enescence, and cell death. Senescence is operationally broadly
eﬁned as a viable growth arrest characterized by the inability
f affected cells to resume proliferation in the presence of appro-
riate mitogenic factors. While multiple cellular and molecular
eatures, including increased cell size, accumulation of lysosomes,
pregulation of cell cycle inhibitors, presence of senescence-
ssociated heterochromatic foci (SAHF), and positive staining for
enescence-associated beta-galactosidase (SA-Gal) activity, have
een associated with senescent cells, no single feature is a univer-
al and speciﬁc marker of senescence. Experimental and clinical
vidence indicate that an intact senescence response is important
or preventing unregulated growth and malignant transformation.
n addition, the ability to undergo senescence can determine the
fﬁcacy of targeted cancer therapies. As described below, however,
enescence is not a discrete mechanism or pathway that can be eas-
ly classiﬁed as either intact or entirely non-functional. Instead, it is
 process that can result from many different inputs with degrees
f sensitivity dictated by intrinsic as well as extrinsic factors.hed  by  Elsevier  Ltd.  This  is  an  open  access  article under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
2.1. Telomerase repression
In the absence of externally or oncogenically induced stresses,
telomerase repression may  be the only physiological impedi-
ment to indeﬁnite replication. Replicative senescence, as originally
described by Hayﬂick in cultures of cells from non-malignant tis-
sues, is due to natural repression of telomerase and the resulting
DNA damage response that occurs when the number of telomeric
TTAGGG repeat sequences on the ends of chromosomes becomes
too few to support the assembly of stable telomere complexes
[1,2]. Structures formed through interactions of TTAGGG repeat
sequences with a protein complex referred to as shelterin function
to “cap” the chromosome ends, protecting against DNA degrada-
tion, recombination, and chromosome fusion [3]. The telomeric
TTAGGG repeats are replenished by telomerase [4], a ribonucleo-
protein complex that consists of a catalytic reverse transcriptase
protein subunit (hTERT, TERT) [5–7], an RNA template (hTR, TERC)
[8–10], and other accessory proteins, including the RNA-modifying
protein dyskerin [11,12]. The presence of hTERT and hTR are the
minimum requirements for recapitulation of telomerase activity
in vitro. Telomerase activity and telomere length elongation in can-
cer are associated with up-regulation of both hTR and hTERT, while
overexpression of hTR has been shown to boost telomerase activ-
ity and more dramatically extend telomere length in cells that
express endogenous or ectopic hTERT [13–15]. Thus both telome-
rase components restrict telomerase activity and telomere length
in vitro, illustrating the fact that both components are required
for a functional telomerase holoenzyme. Although hTERT was ini-
tially considered as the limiting component of telomerase, evidence
from biochemistry, promoter studies, mouse models, and human
tumors has demonstrated contexts where hTR limits telomerase
enzyme levels and telomere maintenance [13–18]. At early embry-
onic stages, the hTERT gene and telomerase activity are expressed
at high levels in many tissues [19,20]. The hTERT gene then under-
goes repression as embryonic cells differentiate into adult somatic
cells [21]. From the neonatal period onward, hTERT transcripts
and telomerase activity are nearly or completely undetectable in
most human tissues [19,22,23], except in some highly prolifera-
tive tissues, such as lymphoid cells and tissue stem and progenitor
cells [24–27]. In vitro, attrition of TTAGGG repeats upon successive
divisions in cells lacking sufﬁcient telomerase activity ultimately
results in DNA damage responses including growth arrest, followed
by cell enlargement, chromatin condensation, and vacuolization
– characteristic features of senescent cells. Multiple and distinct
human cancer precursor lesions, but not corresponding malig-
nant cancers, are composed of cells that display signs of telomere
dysfunction-induced senescence [28]. Ectopic hTERT expression in
many cell types prevents these senescent changes by stabilizing
telomeres and extending replicative lifespan [29–32]. While not
intrinsically essential for malignancy [33], an extended lifespan or
“immortalization” permits clonal cell lineages to accumulate rare
genetic and epigenetic aberrations that together can cause malig-
nant transformation.
In the absence of a telomere maintenance mechanism, telom-
eres shorten with each round of cellular replication to eventually
S ancer
r
f
f
d
i
t
s
a
p
a
t
c
a
t
e
a
a
d
t
f
b
t
m
B
m
c
d
T
i
p
d
c
a
m
a
o
m
[
2
c
b
f
o
m
o
t
a
w
a
f
r
p
r
k
s
f
p
h
h
ﬁ
h
(106 P. Yaswen et al. / Seminars in C
each critically short lengths that are unable to support stable
ormation of shelterin protein complexes that protect telomeres
rom DNA damage surveillance mechanisms [34]. In normal cells,
ysfunctional telomeres and abnormal chromosomal structures
nitiate a p53-mediated DNA damage response [35]. The p16/pRB
umor suppressor pathway is also activated during replicative
enescence in response to telomere dysfunction and DNA dam-
ge [36,37]. Activation of these tumor suppressors halts cell cycle
rogression, initiates senescence, and prevents the propagation of
bnormal chromosomes. However, genetic or epigenetic aberra-
ions in p53 and/or p16/pRB pathways enable otherwise normal
ells to continue to proliferate. Cells that bypass senescence as
 result of defects in these pathways are subject to continued
elomere shortening and telomere dysfunction with consequential
volution of complex karyotypes [38–40]. Critically short telomeres
re fusogenic, resulting in formation of unstable structures, such
s dicentric and ring chromosomes [38,41]. Continued telomere
ysfunction promotes the development of abnormal chromosomes
hrough breakage-fusion-bridge (BFB) cycles, which are initiated by
used chromatids [40,42]. During BFB cycles, fused chromatids form
ridges during anaphase. Chromatin bridges break as cells con-
inue through mitosis, resulting in uneven segregation of genetic
aterial and unstable chromosome structures, which fuel further
FB events in daughter cells. BFB cycles continue until abnor-
al  chromosome structures are lost or stabilized [43]. Resulting
hromosome abnormalities include non-reciprocal translocations,
eletions, gene ampliﬁcations, and whole chromosome losses [43].
hese types of chromosomal aberrations have been demonstrated
n association with telomere dysfunction in cell culture models,
53-null mice, tumor-derived cell lines, and pre-malignant con-
itions [38,40,42,44–49]. They are also the hallmarks of human
arcinomas that feature chromosomal instability [46,50–54]. By
ccelerating the rate and accumulation of molecular changes, telo-
ere dysfunction-driven chromosomal instability may  result in
ctivation of telomerase, activation of oncogenes and/or silencing
f tumor suppressor genes, which ultimately cooperate to promote
alignant transformation, tumor progression, and drug resistance
44–48,52,54,55].
.2. Oncogenic stress
In contrast to replicative senescence, oncogene-induced senes-
ence (OIS) often occurs independently of telomere status [56,57],
ut shares many of the same morphological and biochemical
eatures [36,58–61]. OIS is observed after ectopic expression of
ncogenic RAS, and many of its effectors, including activated
utants of RAF, MEK, B-RAF, PI3K, AKT, and PIM [62–66], and
ther oncogenes such as CDC6, cyclin E and STAT5 [67]. Also, func-
ional abrogation of tumor suppressors such as PTEN, pRB, Spn,
nd NF1, induces senescence-like responses [68]. Stress associated
ith aberrant DNA replication caused by these oncogenic changes
ppears involved in OIS [69–72]. Although the mechanism is not
ully understood, it may  be due to increased expression of positive
egulators of S-phase. Consequently, replicons reﬁre or terminate
rematurely, generating DNA breaks that initiate a DNA damage
esponse and phosphorylation of p53 by DNA damage response
inases. Components of the MAPK cascade also increase the expres-
ion of the tumor suppressor ARF [73], and initiate a negative
eedback loop that ultimately inhibits H/MDM2 [65], resulting in
53 stabilization.
The presence of senescent cells induced by oncogenic signaling
as been documented in several precancerous tissues of both
uman and mouse, indicating that OIS occurs in vivo [74–78]. The
rst direct evidence of cellular senescence in a growth-arrested
uman neoplasm was reported in benign human melanocytic nevi
moles) [77]. Cells in nevi carry an activated oncogene product Biology 35 (2015) S104–S128
(B-Raf-E600), express elevated levels of the tumor suppressor p16,
undergo long-term cell-cycle arrest, and display abundant SA--
Gal activity. In addition, they do not show detectable signs of
telomere erosion, suggesting that they have undergone OIS  rather
than replicative senescence. These and similar results reported by
others [79] suggest that OIS in nevi acts as a barrier to melanoma
development.
2.3. External agent-induced stress
Conventional genotoxic radiotherapy and chemotherapeutic
regimens are potent inducers of senescence in cancer cells in vitro
and in vivo (reviewed in [80]). Although this senescence response
has been shown to involve many of the same DNA damage
response mediators (e.g., ATM, ATR, Chk1, Chk2) as those acti-
vated by telomere dysfunction and oncogene activation, it is
noteworthy therapeutically that cancer cells lacking functional
tumor suppressors such as p53 or pRB often retain the capac-
ity to undergo external agent-induced senescence. While in some
cases, senescence-inducing drugs clearly act through the genera-
tion of DNA damage, in other cases the mechanisms involve only
alterations in DNA structure and function (e.g., inhibition of DNA
methylation or histone acetylation). Still other compounds may
induce senescence through direct or indirect stimulation of stress
sensitive kinases, creating imbalances in mitogen signaling path-
ways [81].
The chief clinical advantage of targeting senescence rather than
outright cell death as a desired endpoint is that drug doses required
to achieve cancer cell senescence are often much lower than doses
required to achieve outright cell death. In prostate cancer cell lines,
for example, a dose of 25 nM doxorubicin is sufﬁcient to induce
senescence, while doses >250 nM are necessary to cause cell death
[82]. In practical terms, treatment with lower doses of genotoxic
drugs that are sufﬁcient to induce senescence but not cell death
could provide equivalent or prolonged patient survival with fewer
and less severe side effects. There are caveats to this approach, how-
ever, as mentioned elsewhere in this review. Chief among them
are the questions of senescence reversibility and pro-tumorigenic
paracrine effects of senescent cells that are not cleared by the
immune system.
3. Mediators of senescence
Gene expression proﬁling has revealed that there is limited
overlap among genes exhibiting altered expression in cells induced
to undergo senescence by telomere shortening, oncogene induc-
tion, or external agents [83–88]. The data indicate that fundamental
differences exist in gene regulation during senescence activated
by various signals in different cell types, despite similarity in the
resulting phenotypes. Despite differences in upstream signaling,
however, induction of senescence often involves convergent inter-
dependent activation of tumor suppressors p53 and p16, the former
protein initiating and the latter maintaining the response [89,90].
While this sequence is demonstrable in lymphoma cells exposed
to cyclophosphamide [91] and ﬁbroblasts exposed to activated
Ras [59], in other cases, such as human mammary epithelial cells
exposed to suboptimal culture conditions [48,92] and melanocytes
which acquire B-RAF mutations [93], p16 activation and senes-
cence occur independently of p53 activation. Although p53 and p16
are clearly involved in establishing senescence growth arrest, their
precise roles in this process are incompletely understood.3.1. p53
The importance of p53 in senescence was determined by inhib-
iting p53 function with dominant negative mutants, speciﬁc p53
ancer Biology 35 (2015) S104–S128 S107
a
S
t
t
w
w
p
c
P
M
l
f
s
p
ﬁ
c
t
m
c
o
i
i
i
[
t
p
t
d
i
d
c
i
t
R
c
E
s
a
H
(
d
T
i
3
m
p
c
k
o
v
p
o
r
c
i
c
e
p
g
p
i
t
Fig. 1. A simpliﬁed scheme is presented of hypothetical alternative phosphoryla-
tion states and growth arrest functions of RB family proteins. Gray circles represent
phosphate groups added to RB family proteins by different cyclin-CDK complexes.P. Yaswen et al. / Seminars in C
ntisense mRNA, oligonucleotides or viral oncoproteins (such as
V40 T antigen or HPV16 E6); such treatments were sufﬁcient
o substantially extend the lifespan of several cell types in cul-
ure [94]. Consistent with these ﬁndings, senescence is associated
ith the transactivation of p53 in cultured cells [95]. Coincident
ith telomere shortening and DNA-damage checkpoint activation,
53 is also activated in vivo [45]. Deletion of p53 attenuated the
ellular and organismal effects of telomere dysfunction [45,96].
roteins that regulate p53 have also been implicated in senescence.
DM2  has p53 ubiquitin ligase activity and forms an autoregu-
atory loop with p53 [97]. Overexpression of MDM2  targets p53
or degradation and induces functional p53 depletion [98]. Expres-
ion of another factor upregulated in senescence, ARF, can release
53 from MDM2  inhibition and cause growth arrest in young
broblasts [98]. Seeding mouse embryonic ﬁbroblasts (MEFs) into
ulture induces ARF synthesis, which continues to accumulate until
he cells enter senescence [99]. MEFs derived from ARF-disrupted
ice [99] or wild type ﬁbroblasts expressing an ARF antisense
onstruct [100] are efﬁciently immortalized. Consistent with this
bservation, overexpression of MDM2  in MEFs produces efﬁcient
mmortalization [100].
Senescence effects of p53 are mediated in part through
ncreased expression of the CDK inhibitor p21WAF1 [101–103]. p21,
n turn, prevents hyperphosphorylation and inactivation of pRB
104,105]. In some human cells, elimination of p21 is sufﬁcient
o bypass senescence [101]. However, in MEFs, the absence of
21 does not prevent senescence [106,107]. This ﬁnding indicates
hat at least one additional downstream effector can indepen-
ently mediate p53-induced senescence. Candidate p53 effectors
nclude 14-3-3 and GADD45, which inhibit G2/M transition, or p53-
ependent transcriptional repression of c-Myc, which results in G1
ell cycle arrest [108]. Other signals may  cooperate with p53 to
nduce senescence. For example, Ras-induced activation of PPP1CA,
he catalytic subunit of PP1, has been shown to be necessary for
as-dependent senescence [109]. Independently of p53, PPP1CA
an stabilize the active unphosphorylated form of pRB. In MEFs,
2F transcription factor associated repressor complexes are down-
tream targets of p53-induced proliferation arrest [110], indicating
 convergence of the p53 and p16/pRB pathways at the level of E2F.
owever, in many human cells, inactivation of either p53 or pRB
e.g., by viral oncoproteins or anti-sense oligonucleotides) indepen-
ently and synergistically extends replicative life span [111–113].
hese ﬁndings suggest that although the p53 and pRB pathways
nteract, they may  also act separately to establish senescence.
.2. p16/pRB
While the causes of p16 induction remain to be deﬁned, its
echanism of action has been well characterized. The binding of
16 to cyclin dependent kinases (CDKs) 4 and 6 induces allosteric
onformational changes that disrupt the interaction of these
inases with D-type cyclins [114], thus antagonizing activation
f the CDKs. Through binding and inactivation of CDKs, p16 pre-
ents phosphorylation and inactivation of pRB and similar “pocket”
roteins, p107 and p130. This canonical description, while valid,
bscures the differences in RB family functions that distinguish
eversible cell cycle arrest from irreversible senescence-associated
hanges. Despite the similarities among RB family proteins, defects
n pRB, but not in p107 or p130, have been associated with human
ancers. This suggests that pRB has unique tumor suppressor prop-
rties not attributable to p107 or p130. In support of this concept,
RB has been shown to be preferentially associated with E2F tar-
ets involved in DNA replication during OIS, and suppression of
RB, but not p107 or p130, allowed continued DNA synthesis after
nduction of oncogenic RAS [115]. The pRB protein contains mul-
iple phosphorylation sites and interacts with multiple proteinThe primary sites of action of endogenous CDK inhibitors, p16 and p21, as well as
the small molecule inhibitor, PD0332991, are also shown.
complexes. It remains to be determined whether the spectrum of
pRB dependent changes in a given cell type under speciﬁc condi-
tions is simply determined by the duration of pRB activation or
by qualitative differences in pRB modiﬁcations/binding interac-
tions. Changes initiated by p16 expression are qualitatively and
quantitatively distinct from those in cells undergoing transient
pRB-dependent growth arrest. For example, in U2OS cells exposed
to p16, pRB augments p130 at E2F-regulated promoters. Dean
and co-workers [116] used chromatin immunoprecipitation (ChIP)
assays to assess protein association with the E2F responsive cyclin
E and A promoters. A 6-day induction of p16 resulted in a dramatic
increase in pRB and E2F-4 associated with these promoters. Addi-
tional promoter-speciﬁc changes in the extent of binding to histone
deacetylase HDAC1, SWI/SNF chromatin remodeling complex com-
ponents BRG1 and Brm, and polycomb group protein HPC2 were
noted.
Distinctions in pRB-associated phenotypes may be due to dif-
ferences in the functionality of different phosphorylated forms of
pRB (Fig. 1). Although growth factors are required for cyclin D1
synthesis, transiently growth-arrested cells often contain signiﬁ-
cant amounts of cyclin D3 associated with CDK4, and the level of
CDK4 activity is sufﬁcient for cell cycle progression if CDK inhibitors
are removed [117]. Thus in transiently growth-arrested cells, pRB
may  be held preferentially in a hypophosphorylated rather than an
unphosphorylated state. While many past studies have relied on
the effect of hyperphosphorylation on the electrophoretic mobility
of pRB to distinguish the hyperphosphorylated from the hypophos-
phorylated form, few have distinguished the unphosphorylated
from the hypophosphorylated form [118]. E2Fs are more easily
co-immunoprecipitated with the hypophosphorylated form of pRB
than the unphosphorylated form of pRB in peripheral blood lym-
phocytes (PBLs) during early G1 [119]. Interestingly, transduction
of p16 protein into PBLs leads to loss of pRB hypophosphoryla-
tion and loss of detectable pRB association with E2F-4. The lack
of detectable association might be due to reduced afﬁnity of the
unphosphorylated form of pRB for E2F-4, or alternatively to rel-
ative insolubility of larger chromatin complexes containing both
pRB and E2F-4. Regardless of the interpretation, the results suggest
that pRB maintained in a minimally or completely unphospho-
rylated state in the presence of p16, is likely to have properties
that differ from those of the hypophosphorylated form. Conﬁrma-
tion of this concept is apparent in the results of an expression
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roﬁling study of rat ﬁbroblast cell lines [120]. In this study, the
ffects on global gene expression of a pRB allele refractory to cyclin-
DK phosphorylation (the presumed state of pRB in the presence of
16) were compared to those of E2F-2 overexpression. The targets
f unphosphorylated pRB were consistent with genes downregu-
ated by p16 overexpression, but showed lower correspondence to
enes stimulated by E2F-2. Similar results using human U2OS cells
ere reported [121].
.3. pRB-mediated heterochromatin formation during cellular
enescence
pRB can play an active role in the formation of senescence-
nduced heterochromatic foci (SAHF) in human cells. Originally
haracterized in senescent ﬁbroblasts [122], these foci consist of
eorganized DNA and are enriched for proteins normally associated
ith heterochromatin, such as histone H3 methylated on lysine 9
H3-K9Me), and heterochromatin protein 1 (HP1) proteins , , and
. The formation of SAHF was slow, taking several days or weeks,
epending on the initiating stimulus, and was reported to coin-
ide with the enhanced association of E2F-target promoters with
eterochromatin proteins. Notably, these changes were blocked by
xpression of the adenoviral E1A protein, which inactivates pRB
nd prevents senescence. Interestingly, senescent BJ ﬁbroblasts,
hich poorly express p16 and were less stably arrested [122], dis-
layed fewer SAHFs than senescent ﬁbroblasts that express higher
mounts of p16 [123].
The chromatin-based role of pRB in transcriptional repression
s complicated, with multiple factors cooperating for transcrip-
ional repression of speciﬁc promoters. For example, repression of
yclin A has been shown to be dependent on SWI/SNF chromatin
emodeling, whereas other forms of transcriptional repression have
een shown to be dependent on histone deacetylases or polycomb
epressor components [116,124–126]. In addition to the E2Fs, pRB
an also associate with HP1 and histone methyltransferases such
s SUV3-9H1, raising the possibility that pRB helps direct the pro-
ess of histone methylation and HP1 recruitment to E2F responsive
romoters during senescence. Consistent with this possibility, pRB
howed colocalization with SAHFs in the nuclei of senescent cells,
hich was greater than that observed for p107 and p130 [122].
dditional work [127] has shown that p16-dependent repression
y pRB at E2F target gene promoters involves the establishment
f a stable repressor complex that is not displaced by the overex-
ression of E2F-1. Rather than displacing pRB, excess E2F-1 instead
ecruits more pRB, leading to direct transcriptional repression. In
ontrast, Rb family members, p130 and p107, which have not been
emonstrated to be tumor suppressors, bind preferentially to tar-
et promoters in the absence of growth factors and in proliferating
ells, respectively, and these repressor complexes are displaceable
y E2F-1. HP1, which interacts with pRB, is associated with these
istinct repressor complexes and follows a similar pattern of sta-
ility/displaceability. Efﬁcient growth arrest by p16/pRB in MEFs is
ependent on H3-K9Me, which provides a binding site for HP1. Dif-
erences in the stability of repressor complexes at promoters may
nderlie the different roles of pRB versus p130 and p107 in cell cycle
egulation and tumor suppression [127].
Although the mechanisms responsible for formation and prop-
gation of heterochromatin remain to be characterized, H3-K9Me,
rimethylation of histone H4 lysine 20 (H4-K20Me), and recruit-
ent of HP1 appear to be involved [128,129]. Trimethylation of
eterochromatic histone H3-K9 is accomplished by Suv3-9H1 and
uv3-9H2 [130], while Suv4-20H1 and Suv4-20H2 trimethylate
istone H4-K20 [129]. pRB physically interacts with both these
ethyltransferase complexes, although the biological signiﬁcance
f these interactions remains unclear [131,132]. Importantly, H3-
9Me was enriched at proliferation-associated gene promoters Biology 35 (2015) S104–S128
speciﬁcally in senescent cells, concomitant with the appearance of
SAHFs, but not in quiescent cells [122]. In addition, Suv3-9, which is
responsible for H3-K9Me, has been found to be required for OIS in
murine lymphocyes, and for suppression of lymphoma [64]. There-
fore senescent cells are thought to maintain growth arrest through
the formation of heterochromatin at proliferation-promoting gene
loci.
Molecular details of SAHF formation and stability remain to
be determined. In addition to pRB, H3-K9Me, and HP1, SAHFs
are known to be enriched in a histone H2A variant, macroH2A,
previously associated with silenced chromatin [133], and HMGA
proteins, which appear to be essential for SAHF formation [123].
Two evolutionarily conserved histone chaperones, HIRA and ASF1a,
are also known to cooperate with pRB in the formation of SAHFs
[134]. These proteins, human orthologs of proteins known to cre-
ate transcriptionally silent heterochromatin in yeast, ﬂies, and
plants, may  generate more extensive heterochromatin domains at
positions designated by pRB. In WI38 human ﬁbroblasts induced
to undergo senescence by the introduction of an activated Ras
oncogene, each chromosome condenses into a single SAHF focus
[135]. The chromosome condensation is hypothesized to depend,
in part, on increased nucleosome density due to HIRA/ASF1a-
mediated nucleosome deposition. This chromatin condensation
occurs prior to the accumulation of H3-K9Me and deposition of
HP1 and macroH2A in chromatin, leading to speculation that HP1
proteins do not contribute to the acute onset of the senescent phe-
notype, but that instead, they might be required for the long-term
maintenance of SAHF and the senescent state. Similarly, recent
work using the same inducible OIS model has shown that the global
pattern of repressive histone marks was  largely unchanged during
senescence, indicating that SAHF formation largely involves repo-
sitioning of chromatin bearing pre-existing marks rather than de
novo formation of new marks [136]. This work also showed that
H3-K9Me and H3-K27Me marks were not necessary for SAHF for-
mation. However, the contribution of these individual components
to senescence irreversibility remains to be determined.
4. Evidence that senescence is tumor suppressive
A protective role of senescence has been inferred in murine
models of lung adenomas, T-cell lymphomas, prostate tumors, and
pituitary tumors [74–76,78]. In one example, Ras-V12 knock-in
mice were shown to develop lung adenomas that were character-
ized by low proliferative indices, elevation of SA--Gal activity, and
other senescence markers [137]. By contrast, the few adenocarcino-
mas  that did emerge showed considerable proliferative activity and
lacked senescence markers. In another example, Ras-V12-driven
mouse T-cell lymphoma cells in which apoptosis was blocked
entered senescence after drug therapy, and senescence was shown
to be dependent on the chromatin-remodeling enzyme Suv3-9H1
[74]. In another study, p53 and p16 were found to cooperate in
murine lymphoma cells, engaging a program of prolonged cell-
cycle arrest in response to the alkylating agent, cyclophosphamide
[91]. Mice bearing tumors capable of p16-induced senescence had
a much better prognosis following chemotherapy than those har-
boring tumors with p16 defects. The study showed further that p16
loss and disruption of apoptosis by Bcl2 act independently to pro-
mote drug resistance. In a prostate tumor model, p53-dependent
cellular senescence could be triggered by inactivation of the tumor
suppressor, PTEN [75]. Similar ﬁndings have been reported in E2F-3
driven pituitary gland tumors [138].Direct evidence that senescence is tumor suppressive has been
generated using inducible murine models. In a model for p53-
dependent liver cancer, the effect of p53 restoration was studied
in established liver carcinomas [139]. Hepatoblasts expressing
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 conditional p53 shRNA produced invasive hepatocarcinomas.
oon after re-expression of p53, the tumors underwent dramatic
egression associated with cellular senescence. The senescent cells
cquired a speciﬁc gene expression proﬁle that included upregula-
ion of inﬂammatory cytokines; this led to activation of the innate
mmune system, which was responsible for clearing the tumor. This
ork established a link between the cellular senescence program
nd the innate immune system in suppressing tumorigenesis. Sim-
lar work by others using a mouse osteosarcoma model has also
hown that re-expression of endogenous p53 leads to a senescence-
ike cell-cycle arrest and complete tumor regression [140].
Correlative data indicate that stress-induced senescence is
umor suppressive in human tissues as well. In malignant
ells, senescence is a well-documented consequence of various
hemotherapeutic regimens [80]. In a speciﬁc example in which
A-gal activity was used as a marker of senescence, 15/36 breast
umor resections after neoadjuvant chemotherapy (cyclophos-
hamide, doxorubicin, and 5-ﬂuorouracil) were found positive for
A-gal, while only 2/20 untreated tumors showed any SA-gal
taining, suggesting that the induction of senescence may  be favor-
bly related to treatment outcome [141]. The senescence response
as associated with those tumors bearing wild-type p53 alleles
nd exhibiting p16 expression. Interestingly, the normal tissue of
hemotherapy-treated patients was completely negative for SA-
gal, indicating potential selectivity in the senescence response.
imilar observations have been made in lung tumors resected from
atients receiving neoadjuvant chemotherapy [142].
. Evidence that senescence can promote malignancy – the
enescence associated secretory phenotype
Unlike cells that are removed by other tumor suppressor
echanisms such as programmed cell death, senescent cells can
ersist and continue to actively interact with surrounding cells
nd tissues for extended periods of time. Defective elimination
f senescent cells may  lead to unregulated accumulation in aging
issues and at sites of age-associated pathologies including can-
er [75,86,93,143–154]. Experimental removal of accumulated p16
ositive senescent cells in a progeroid mouse model was sufﬁcient
o reverse some age-associated pathologies, demonstrating that
ccumulation of senescent cells is responsible for some tissue dys-
unctions [155]. In the context of tissue repair, current evidence
uggests that senescent cells are normally eliminated in a pro-
ess that involves immune system functions [156–161]. Whether
o stimulate tissue repair or their own elimination, senescent
ells actively interact with their tissue microenvironment, possibly
hrough direct cell–cell contacts, and undoubtedly using paracrine
ignals (secretion). Protein secretion by senescent cells has been
ollectively termed the Senescence-Associated Secretory Pheno-
ype (SASP) [162]. Current data support the idea that senescent
ells interact with and modify their microenvironment using this
ecretory program. Signaling elements regulating the SASP include
he DNA damage response (DDR), p38MAPK, the JAK/STAT pathway
nd transcription factors such as NF-B and C/EBP  [163–168].
The SASP was originally documented indirectly through the
bility of senescent cells to inﬂuence the biology of other
ells [169]. Subsequently, mRNA proﬁling, targeted proteomics
antibody arrays), and genome-wide RNA interference screens
ave been used to characterize SASP factors and their effects
163,164,170–174]. Multiple SASP factors have been directly val-
dated for their ability to modulate the biology of senescent cells
r that of surrounding cells [175–177]. While individual SASP
omponents may  vary depending on cell type and context, a few
biquitous SASP factors have emerged, including pro-inﬂammatory
L6 and IL8, extracellular matrix remodeling MMP3, and growth Biology 35 (2015) S104–S128 S109
promoting GroA [170]. The SASP supports positive aspects of
cellular senescence such as growth arrest and proper tissue
repair (Fig. 2). Autocrine activities include reinforcement of p53-
dependent growth arrest via cytokine signaling loops [163,164].
Paracrine activities include orchestrating the activity of special-
ized repair cells, including activated stellate cells, ﬁbroblasts and
immune cells, which are responsible for the resolution of wound
responses [156,157,159]. The SASP is also believed to modulate the
clearance of senescent cells by the immune system [157,159].
In some contexts, however, presumably when senescent cells
cannot be properly cleared by the immune system, negative con-
sequences can occur [153,178–180]. Senescent cells may  gradually
accumulate and displace normal cells, rendering affected tissues
dysfunctional. Senescent cells may  also modify the local microen-
vironment making it more supportive of survival and/or growth of
potential pre-neoplastic cells. Following cancer therapy, surviving
cells exhibiting the SASP could create a protective microenvi-
ronment, or a niche, for subsets of cancer cells that can initiate
cancer recurrence. Cancer promoting effects of speciﬁc SASP fac-
tors have been shown in vitro and in vivo. For example, MMP3
secretion by senescent cells perturbed the proliferation and dif-
ferentiation of cultured normal breast epithelial cells [181] while
secretion of HGF, AREG, or GroA increased proliferation of cul-
tured cancer cells [173,174,182]. Cytokines IL6 and IL8 promoted
invasiveness and epithelial to mesenchymal transition (EMT) of
established cancer cell lines [173]. In xenograft models, senes-
cent cells accelerated the growth of weakly tumorigenic human
cell lines [169]. This was  attributed to MMP3  [183], but may also
involve other MMPs  secreted by senescent cells [160]. Secretion of
VEGF may  be responsible for increased vascularization observed in
xenograft models incorporating senescent cells [184]. Additional
data support a role of the SASP in cancer recurrence. For exam-
ple, IL6 secretion by senescent cells in post-chemotherapy murine
thymus was sufﬁcient to create a protective niche for subsets
of lymphoma cells [167,185]. Similarly, SASP factors were linked
to recurrence of chemotherapy treated murine mammary can-
cers [186]. Finally, in another murine cancer model, secretion of
SASP factor WNT16B by senescent stromal cells supported contin-
ued growth of prostatic epithelial cancer cells after chemotherapy
[187]. Importantly, increased WNT16B levels were also detected in
post-therapy human prostate, ovarian, and breast cancers.
6. Determinants of senescence stability
Contrary to popular belief, the senescence growth arrest is
not always irreversible. Since senescence is a response to stress,
genomic and epigenomic aberrations that ameliorate stress (e.g.,
telomerase activation) or compromise cellular ability to sense or
transduce stress-related signals (e.g., p53 inactivation) have the
potential to promote immortalization and resistance to therapeu-
tically induced senescence. Evidence obtained using cell sorting
and videomicroscopy showed that fully senescent non-malignant
human keratinocytes are capable of spontaneously yielding mitot-
ically competent progeny [188]. Similarly, ﬂuorogenic tracer and
video microscopy were used to show that morphologically senes-
cent cells in cultures of human mammary epithelial cells expressing
the NeuT oncogene are capable of dividing [189]. In addition,
fully senescent human ﬁbroblasts and human mammary epithelial
cells could be stimulated to resume proliferation by inactivating
p53 – provided the cells had not expressed p16 [122]. Human
mammary epithelial cells lacking the ability to express functional
p16 are prone to unstable growth arrest and chromosomal rear-
rangements during telomere dysfunction-induced senescence [48].
The genomic instability generated by telomere dysfunction can
complement pre-existing genetic aberrations to yield immortal
S110 P. Yaswen et al. / Seminars in Cancer Biology 35 (2015) S104–S128
Fig. 2. The senescence associated secretory phenotype (SASP) aids in the clearance of senescent cells, but can potentially promote proliferation of tumor cells that are not
stably  growth arrested. Cell-autonomous growth arrest associated with senescence prevents the proliferation of damaged cells and is at least partially dependent on p53/pRB
pathways. In normal tissues, senescence also results in the activation of non-autonomous secretory factors that participate in wound response signaling, culminating in
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reatment with therapeutic agents. However, cancer cells often harbor compromise
lterations in the types or abundance of secretory factors released by such cells m
hat  have escaped cell death. Important questions regarding the impact of senescen
ells [190,191]. Cells that emerge from such cultures display gross
enetic aberrations, many of which are also seen in human cancers
54], suggesting that the same molecular lesions that enable escape
r circumvention of senescence in vitro occur during oncogenesis
n vivo.
Determinants of the stability of the senescence response have
ot been well characterized. Yet, the implications of delayed cell
ycle re-entry or permanent senescence for patient prognoses are
rofound. In the former case, transient senescence may  allow tumor
ells time to repair or accommodate the chemotherapeutic stress
e.g., damaged DNA), effectively conferring drug resistance [192].
onversely, therapeutic efﬁcacy would be enhanced by enforce-
ent of stable senescence in cancer cells that manage to retain
iability in the face of a therapeutic challenge. The mechanisms
etermining these exclusive outcomes are poorly understood,
lthough clinical and experimental data indicate that the status of
21 and p16, and associated tumor suppressors (e.g., p53, pRB) play
ritical roles.
The reversibility of p16-induced growth arrest has been exam-
ned in human U2OS cells in which the transcription of an
xogenously introduced p16 gene was regulated by tetracycline
193]. Induction of p16 for one day arrested most cells in the G1
hase of the cell cycle; if the inducer was then removed, p16 levels
eturned to baseline and growth resumed within 3–5 days. If, how-
ver, p16 was induced for 6 days, DNA synthesis remained strongly
nhibited and the cells acquired morphological features of senes-
ence. These results demonstrated that sustained p16 expression is
ufﬁcient to impose a stable block to cell proliferation that becomes
ndependent of p16 expression after a deﬁned period of time.
In another model employing breast cancer cell lines stably
xpressing shRNAs against each of the individual RB family pro-
eins, p16 induction still resulted in irreversible G1 growth arrest
n each case [194]. This ﬁnding suggests that there is some redun-
ancy in the ability of the individual RB family proteins to mediate
rreversible growth arrest. Cases of functional redundancy within
his gene family have been reported in a number of murine and
uman cell types [195,196]. This ﬁnding may  explain why  aber-
ations in upstream regulators such as p16, cyclin D1 and CDK4,
hich presumably affect the regulation of all three RB family pro-
eins simultaneously, are more common than aberrations in the
ndividual RB family proteins themselves in some cancers. From ativation of non-autonomous secretory factors can be altered and/or increased by
/pRB pathways, and as a result, growth arrest may not occur or may  be less stable.
erfere with immune clearance and/or stimulate the growth of nearby cancer cells
the context of cancer therapy are highlighted in red.
clinical standpoint, it is encouraging that even aggressive cancer
cells lacking both p53 and pRB tumor suppressors, are susceptible
to induction of irreversible senescence. This suggests that therapies
employing small-molecule inhibitors of CDK4/6 may be effective
even in some tumors lacking functional pRB.
A representative small molecule CDK inhibitor that has recently
been approved for clinical use is PD0332991 (Palbociclib; Supple-
mentary Table 1). This drug has been tested against 39 individual
serine, threonine, and tyrosine kinases, representing most of the
primary protein kinase families, and has shown highly selec-
tive inhibition of CDK4 and CDK6 [197–199]. Importantly, oral
PD0332991 administration alone at doses that were well toler-
ated by host animals was  sufﬁcient to cause regression of a variety
of human tumor xenografts [197]. The mechanism by which this
small molecule causes tumor regression in xenograft studies has
been unclear, since in short-term cell culture studies (72 h) it has
been shown to cause cytostasis rather than cytotoxicity [197].
Recent assessment of PD0332991 using short-term growth assays
indicated that it was effective in inducing growth arrest of many
estrogen receptor (ER) positive breast cancer cell lines, but that a
number of ER(−) lines were able to maintain pRB phosphorylation
and proliferation in its presence [200]. Several of the ER(−) cell lines
exhibiting resistance to the CDK4/6 inhibitor retained phosphory-
lated pRB in the presence of the CDK4/6 inhibitor. This indicates
that another kinase, most likely CDK1 or CDK2, was  capable of
phosphorylating and inactivating pRB in the absence of CDK4/6
activity in these cell lines. Thus, in many ER(−) breast cancer cells,
targeting of CDK1 or CDK2 instead of, or in addition to, CDK4
may  be required to initiate senescence. However, if the resulting
senescence response is not stable, this may  be clinically counter-
productive. Indeed this danger was illustrated in a recent report
that showed CDK4/6 inhibition protected ER(−) breast cancer cells
from doxorubicin-mediated cytotoxicity [201].
Supplementary table related to this article can be found, in the
online version, at doi:10.1016/j.semcancer.2015.03.007.7. Defects in telomerase regulation
Telomerase is almost universally re-expressed in cancer cells
and is regulated at multiple levels involving genetic, epigenetic,
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ranscriptional, post-transcriptional, post-translational, and sub-
ellular shuttling mechanisms. At the genetic level, both hTR and
TERT genes have been reported to be ampliﬁed in some tumors.
ncreased hTR gene copy number was detected frequently in head
nd neck and cervical carcinomas [202] while hTERT gene ampliﬁ-
ations have been found in primary cancers and cell lines, including
hose of brain, breast, cervix, liver, and lung [203–205], as well
s primary and metastatic melanomas [206]. In most cases, the
mpliﬁed region encompassed most or all of chromosome 5p
13,203,206]. However in several cases, chromosomal break points
ere mapped to regions close to the hTERT promoter, suggest-
ng that chromosomal rearrangements could either relieve the
romoter from its stringent repressive epigenetic environment or
lace it in the proximity of enhancers at different chromosomal
ites [207]. Genetic polymorphisms may  also contribute to vari-
tions in telomere length and cancer development. In a recent
enome wide association study, single nucleotide polymorphisms
SNPs) in seven loci were found to be associated with differences in
ean leukocyte telomere length and risks of cancer and other age-
elated diseases [208]. These loci corresponded to genes encoding
TERT and hTR, as well as other proteins involved in telomerase
omplex assembly and telomere maintenance. SNPs in multiple
egions of the hTERT locus, including the promoter and down-
tream introns, were shown to be associated with telomere length
nd risks of various malignancies, including breast, ovarian, and
rostate, glioma, lung, and urinary bladder cancer [209–211].
Both the hTR and hTERT genes are subject to tumor speciﬁc
pigenetic regulation. H3-K9Me marks were increased at the hTR
romoter in normal ﬁbroblasts and in several ALT cell lines with
ow hTR expression in comparison with telomerase positive can-
er cell lines, suggesting a role in hTR suppression, while H3-K4Ac,
4-K4Ac, H3-K9Ac and H3-K4Me were associated with hTR expres-
ion. Similar analysis of the hTERT promoter also revealed H3-K9Me
ssociated with transcriptional suppression and higher levels of
3-K4Ac, H4-K4Ac and H3-K9Ac in cancer cells compared with nor-
al  ﬁbroblasts, though H3-K4Me was not strongly associated with
xpression in the panel tested [212].
In cancer cells lacking chromatin mediated silencing present
n normal cells, both genes are subject to regulation by a wide
ariety of distinct, but overlapping, transcription factors. hTR is
enerally expressed at low levels in normal cells and is substan-
ially up-regulated in cancer cells as shown both by ﬂuorescence
n situ studies of a wide range of tumor samples [213] and by tumor
peciﬁc expression of hTR promoter-driven transgenes in the set-
ing of gene therapy studies [214,215]. The hTR gene promoter is
ctivated by NF-Y, Sp1, pRB and HIF1, and is suppressed by Sp3,
DM2  and active JNK signaling which causes a switch from Sp1
o Sp3 binding at the endogenous promoter [216–218]. However,
eyond these ﬁndings, relatively little attention has been paid in
he literature to hTR transcriptional mechanisms.
In contrast, the hTERT gene has been intensely studied since its
olecular cloning in 1997 (Fig. 3). hTERT transcripts are nearly or
ompletely undetectable in most normal cells, but are expressed
t low levels which are sufﬁcient to drive telomere maintenance
n cancer cells. Substantial work has focused on the core promoter
egion, which is sufﬁcient for tumor speciﬁc activity. This region
ontains a number of binding sites for known transcription factors
ncluding c-Myc, HIF1, ETS, E2F and Sp1/Sp3, which integrate hTERT
ranscriptional responses with a number of important pathways
hat are dysregulated in various tumor types [219–221]. Interest-
ngly, HIF1 is also involved in post-transcriptional regulation of
TERT splicing [222].In general, oncogenic growth promoting pathways have usually
een found to activate telomerase expression and promoter activ-
ty, while pathways controlling growth suppression, cell death and
enescence have the opposite effect. For example, growth factor Biology 35 (2015) S104–S128 S111
signaling through MAPK pathways increases hTERT expression in
part via ETS factors [223]. Interestingly, recent studies have shown
that telomerase can be activated by point mutations in the hTERT
core promoter occurring with particularly high frequency in both
familial and sporadic melanoma samples [224,225]. These muta-
tions occurred more frequently than BRAF or NRAS mutations and
each generated a binding site for ETS family transcription fac-
tors, including the TCF subgroup activated by MAPK and BRAF
signaling.
Other hTERT activation pathways that are frequently deregu-
lated in various cancer settings include those inﬂuenced by CDK2
and CDK4 [226] and AKT [227], whereas deregulated repression
pathways include those inﬂuenced by TGF [228], TNF [229], and
other cell cycle inhibitors [230]. Disrupted developmental path-
ways can cause hTERT expression. For example, the hTERT gene has
been found to be a direct target of the Wnt  signaling [231–233].
The Wnt  signaling pathway is known to play essential roles in
development and stem cell renewal. Binding of Wnt  ligand to its
receptor Frizzled activates GSK3 kinase, which blocks ubiquitin-
dependent degradation of -catenin. Stabilized -catenin enters
the nucleus, forms a complex with LEF/TCF, and activates a set
of target genes including c-Myc. Myc  protein binds to an E-box
element in the hTERT core promoter and activates hTERT tran-
scription. In addition, -catenin can also form a complex with
transcription factor Klf4 and bind to the hTERT promoter directly
[231].
Recently, a whole kinome siRNA screen in ovarian cancer cells
for regulators of the hTERT promoter revealed at least 68 kinases
that participate in pathways upstream of hTERT regulatory tran-
scription factors, underscoring the complexity of the signaling
environment [234]. Hence, it is perhaps more useful and realis-
tic to consider hTERT regulation in a systems context as a dynamic
network, in which cell-speciﬁc mechanisms are likely to come into
play, than to focus on individual factors. For example, while c-Myc
has been shown to activate hTERT transcription in cancer cells and
some normal cells [235], moderate overexpression of c-Myc by
itself is not sufﬁcient for activation of endogenous hTERT genes in
normal human mammary epithelial cells [191]; in the latter case,
additional genomic alterations were needed for telomerase acti-
vation and cellular immortalization. Many other factors bind the
extended hTERT promoter region, co-operating with those at the
core promoter and with upstream pathways. Different combina-
tions of transcription factors may  activate telomerase expression
in speciﬁc cancer cells. Given this complexity, there is clearly a
need for approaches to study telomerase regulation at the systems
level. A possible positive implication of the complexity is that, if
sufﬁciently well understood, it could lead to precise therapeutic
ablation of telomerase expression in cancer cells through com-
binatorial targeting of cooperating factors in speciﬁc cancer cell
contexts.
8. Therapeutic targeting of telomerase
Intrinsic differences in telomere maintenance between normal
and cancer cells provide an attractive therapeutic opportunity. Sev-
eral direct strategies to exploit the dependence of cancer cells
on aberrant telomerase expression for telomere homeostasis and
immortality have been reported. The key advantages of target-
ing telomerase in comparison with most other cancer targets are
its relative universality, criticality and speciﬁcity for cancer cells,
including putative cancer stem cells [236]. Approximately 90%
of human cancers and virtually all adenocarcinomas display sig-
niﬁcantly higher levels of telomerase compared to normal cells,
thereby implicating telomerase as an intriguing target of potential
anticancer therapeutics [22]. No other tumor-associated marker
S112 P. Yaswen et al. / Seminars in Cancer Biology 35 (2015) S104–S128
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iig. 3. Mediators of hTERT activation and repression. Green arrows (top panel) indic
nteractions that inhibit hTERT. Letters indicate mechanism (TR, transcriptional reg
s as widely expressed. Moreover, telomerase, encoded by non-
edundant genes, is the most efﬁcient known mechanism for
aintenance of telomeres and replicative immortality. Although
 telomerase-independent alternative lengthening of telomeres
ALT) mechanism exists for telomere maintenance in cell lines
nd cancers in which telomerase is not active or is suppressed
237,238], some studies suggest that ALT cells are not as biolog-
cally robust as telomerase-positive cancer cells, and may  haveported interactions that activate, while red arrows (bottom panel) indicate reported
n; B, binding; -/+P, de/phosphorylation; IE, inﬂuence on expression).
heightened susceptibility to drug regimens that induce oxida-
tive stress [239,240]. Thus cancers may  be less likely to develop
resistance to telomerase-based therapies than to other targeted
therapies whose targets may be compensated for by functionally
similar proteins and pathways. In addition, the low or transient
expression of telomerase in normal tissues, including normal stem
cells, and the generally longer telomeres in normal stem cells versus
cancer cells, provide degrees of speciﬁcity to telomerase-based
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rugs and reduce the probability of toxicity to normal tissues [241].
ll of these factors suggest that cancer drugs based on telomerase
ight have a high therapeutic index.
Many distinct classes of anticancer compounds directed toward
elomerase can conceivably be developed because of the varied
ellular processes that regulate telomerase expression and activ-
ty. For example, cellular telomerase activity can be controlled
hrough changes in gene transcription and alternative splicing
f the telomerase components, and by the nuclear translocation,
hosphorylation, folding and turnover of individual components
hat lead to and regulate the rate of telomerase complex assembly
nd accessibility to telomeres [242,243]. The therapeutic poten-
ial of targeting telomerase-mediated telomere maintenance in
ancer cells was ﬁrst demonstrated by expression of a dominant
egative mutant form of hTERT (DN-hTERT) in tumor-derived cell
ines [31,244]. These studies showed that inhibition of telomerase
n solid tumor and leukemia cell lines induced progressive telo-
ere shortening and eventual proliferative arrest or cell death
ia apoptosis. They also demonstrated that expression of DN-
TERT inhibited anchorage independent growth and impeded the
evelopment of malignancies in xenografted mice [245–248]. The
nhibitory effects of DN-hTERT were also experimentally demon-
trated using primary AML  cells in vitro and in vivo using a murine
odel [248].
.1. Oligonucleotide inhibitors
Studies that utilized antisense oligonucleotides, including
hemically modiﬁed nucleic acids (PNA) that target hTR, pro-
ided proof-of-principle evidence of the effectiveness of this
pproach as a means of speciﬁcally inhibiting telomerase and
nducing telomere shortening [249–254]. In human tumor cell
ines, 2′-O-MeRNA, phosphoramidate and PNA oligomers induced
elomere shortening with the subsequent onset of apoptosis over
ong-term culture periods [252,254–256]. In particular, a N3′–P5′
hio-phosphoroamidate oligonucleotide targeted to the template
egion of human hTR (GRN163) was shown to have efﬁcacy against
ultiple myeloma and non-Hodgkin’s lymphoma cell lines, as well
s activity toward patient-derived cells [256–258]. The speciﬁcity
f this compound was evidenced by telomere shortening, and by
he relatively high sensitivity of multiple myeloma cells with short
elomeres in comparison to cells with longer telomeres [257,258].
 lipid conjugated form of GRN163, referred to as GRN163L or ime-
elstat, exhibited improved cell uptake and was shown to more
ffectively inhibit telomerase, cause more rapid telomere shorten-
ng and thus elicit more rapid growth arrest than the non-lipidated
ompound [259,260]. Although one study reported that imetelstat
aused cultured mesenchymal stem cells (MSCs) to arrest in G1
hase of the cell cycle, the MSCs were able to resume growth after
metelstat was removed [261]. Therefore, short-term imetelstat
xposure did not appear to induce senescence or cell death in MSCs.
he efﬁcacy of imetelstat against cancer cells was demonstrated in
 variety of preclinical models, including mice xenografted with
uman cell lines derived from liver, breast, lung and prostate can-
ers, as well as multiple myeloma [259,262–265]. Together, the
reclinical studies of imetelstat validated targeting the template
egion of hTR as an effective approach to telomerase inhibition.
owever, evidence also emerged from these studies suggesting
hat in addition to inhibiting telomerase, imetelstat also has off
arget effects that disrupt the cytoskeleton and alter adhesive prop-
rties of tumor cells [266,267]. Inhibition of breast and lung cancer
etastases in an animal model was attributed to this telomerase-ndependent action of imetelstat [266].
Following the success of the preclinical investigations of imetel-
tat, phase 1 clinical trials were initiated in which imetelstat was
ested as a single agent in patients with various aggressive liquid Biology 35 (2015) S104–S128 S113
and solid tumors (Supplementary Table 1). The limited informa-
tion that was  released following the completion of those studies
suggested that imetelstat presented minimal adverse effects, with
thrombocytopenia and neutropenia being the dose limiting toxic-
ity [236] (http://www.geron.com/imetelstat). Subsequent phase II
trials have focused on hematologic disease, childhood CNS malig-
nancies and the application of imetelstat in maintenance therapy
for non-small cell lung cancer and metastatic breast cancer patients
previously treated by standard chemotherapy and surgical debulk-
ing. Data emerging from these trials suggest limited beneﬁt in these
speciﬁc clinical settings. Disappointing progression-free survival
results from a phase 2 trial of imetelstat as maintenance therapy fol-
lowing platinum chemotherapy in patients with non-small cell lung
cancer have led the Geron Corp. to suspend further development of
imetelstat in solid tumors. However, it has been argued that results
from the lung cancer trial showed improved outcomes for a small
subset of patients with tumors that had short telomere lengths.
Among the trials for hematologic disorders, encouraging data from
13 patients treated with imetelstat for essential thrombocythemia
were presented at the annual meeting of the American Society for
Hematology in December 2012. The ability of imetelstat to reduce
platelet counts in essential thrombocythemia is consistent with
earlier trials that reported thrombocytopenia as an adverse effect.
While imetelstat, targeting hTR, was the ﬁrst telomerase
inhibitor to undergo trials in patients, modiﬁed antisense oligonu-
cleotides targeting hTERT mRNA have also been shown to impede
the proliferation of tumor cells. However, in contrast to the lag
period observed in preclinical investigations of imetelstat, the
proliferative defect induced by hTERT inhibition was immediate,
and occurred in the absence of apparent telomere shortening
[268–270]. A modiﬁed oligonucleotide directed toward hTERT
mRNA was  also shown to sensitize leukemic cell lines and primary
cultures established from AML  and CML  patients to the drug cis-
diamminedichloroplatinum. Ribozymes and small interfering RNAs
(siRNAs) targeting hTERT have also been employed to suppress tel-
omerase activity, impede proliferation, and sensitize tumor cells
to cytotoxic drugs [271–275]. The potent anti-proliferative effects
that have been demonstrated in tumor cells depleted of hTERT are
consistent with a body of evidence that describe telomere-length
independent functions of hTERT and gene expression changes
induced by repression of hTERT [276–281]. These observations fur-
ther highlight the potential beneﬁt of direct therapeutic targeting
of hTERT, although the translation of these ﬁndings to the clinic
await the development of new technologies for efﬁcient delivery
of siRNA and ribozymes to tumor cells.
8.2. Small molecule telomerase inhibitors
Small molecular weight compounds that inhibit telomerase
activity have been identiﬁed in screens of chemical libraries
or synthesized based on the structure of the tea catechin,
epigallocatechin-3-gallate (EGCG; see Section 8.4), which is
a known naturally occurring telomerase inhibitor [282–287].
Small molecular weight telomerase inhibitors characterized
to date belong to a range of chemical classes and include
2-[3-(triﬂuoromethyl)phenyl]isothiazolin-3-one (TMPI), Rhoda-
cyanine (FJ5002), N-[3-[(2,3-dihydroxybenzoyl)amino]phenyl]-
2,3-dihydroxybenzamide (MST-312) and (E)-2-(3-(naphthalene-2-
yl)but-2enamido)benzoic acid (BIBR1532). BIBR1532 is one of the
more extensively used inhibitors and was shown to induce telo-
mere shortening, impede proliferation of tumor cell lines in vitro
and limit tumor formation in xenografted mice [284,288,289]. At
a low concentration (10 m),  BIBR1532 had no effect on short-
term proliferation or survival, whereas higher concentrations
(50–80 m)  were acutely cytotoxic. Notably, toxicity was also
observed when telomerase-negative leukemia cells were treated
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ith a high concentration of the BIBR1532. The cytotoxic effects
f BIBR1532 were attributed to telomere uncapping, however non-
elomeric effects have not been ruled out. Limited bioavailability
f this compound has prevented its translation to clinical trials in
atients.
Other indirect approaches to targeting telomerase can and are
eing considered. A range of pathways and mechanisms may  be
ractable for such inhibition. For example, the PI3K-Akt-mTOR
athway regulates cell size, progression of the cell cycle, and cell
urvival, and is considered a master regulator of protein synthesis
290]. mTOR – a serine/threonine kinase – is frequently dysreg-
lated in cancer cells [291]. An association between mTOR and
elomerase activity has been shown using the prototypical mTOR
nhibitor rapamycin that, in addition to its other effects, causes
nhibition of telomerase activity [292–296]. Some phytochemicals
see below) act in a similar manner to rapamycin with respect to
elomerase inhibition [294,297].
.3. Immunotherapeutic approaches
Studies that demonstrated telomerase antigens on the sur-
ace of tumor cells provided impetus for pursuing telomerase
mmunotherapy as a therapeutic approach to the treatment of
he broad spectrum of human malignancies that express telo-
erase [298–300]. Following preclinical studies of telomerase
mmunotherapy for treatment of leukemia and other malignan-
ies [301,302], immunotherapy products were developed for use
n telomerase vaccination clinical trials [236,303] (Suppl. Table 1).
ndeed one product, GV1001, has progressed to phase III clinical tri-
ls, in which it is being used in combination with gemcitabine for
he treatment of pancreatic cancer [236]. Concerns that telomerase
mmunotherapy may  be detrimental to normal hematopoietic pro-
enitor cells were somewhat allayed by investigations that showed
here was no signiﬁcant reduction in the frequency of clonogenic
rogenitor cells or NOD/SCID repopulating cells within the bone
arrow of cancer patients after vaccination [304]. In accordance
ith this result, limited hematologic toxicity, such as grade I anemia
nd thrombocytopenia, were reported to occur during telomerase
accine trials [236].
.4. Telomerase-directed gene therapy
The general aim of most tumor speciﬁc gene therapy is to
electively kill cancer cells while leaving normal cells unharmed
y expressing high concentrations of a therapeutic protein only in
alignant cells. Transcriptional targeting, in which a therapeutic
ene is placed under transcriptional control of a tumor-speciﬁc pro-
oter, is a potentially powerful tool to achieve this aim. Although
heir activities are quite different, the promoters for hTERT and hTR
re attractive candidates for use in gene therapy since they are both
ctive in the vast majority of cancer cells tested [17]. Most telome-
ase gene therapy strategies that have been tested can be broadly
ategorized as cytotoxic gene therapy or oncolytic virotherapy
pproaches, both of which aim directly to kill cells express-
ng telomerase while sparing normal cells that do not, thereby
ircumventing the issue of the phenotypic lag in cells in which tel-
merase activity is merely blocked [17]. Using these gene therapy
pproaches, cell lines covering most of the major common malig-
ancies have been targeted effectively in vitro. Critically, almost all
f these studies have shown speciﬁcity using normal cell strains.
fﬁcacy against xenograft models has also been repeatedly shown
cross multiple tumor cell types. Although there is a concern that
he activities of the core telomerase promoters in normal mouse tis-
ues may  not reﬂect their activities in human, several groups have
hown that systemic delivery of telomerase-speciﬁc gene therapy
onstructs does not result in signiﬁcant off-target liver toxicity. Biology 35 (2015) S104–S128
In addition, the biodistribution of systemically delivered hTR and
hTERT-speciﬁc transgene expression has been investigated by
imaging and reporter assays; activity appears to be low or absent
in normal tissues (for a review of efﬁcacy and selectivity data, the
reader is referred to tables in [17]). Therefore, proof-of-principle
broad spectrum, selective targeting by the telomerase promoters
has been convincingly shown in preclinical models.
8.5. Phytochemicals
Attractive anticancer agents due to their low cost and acces-
sibility in diets, phytochemicals may  have selective telomerase-
inhibiting and senescence-inducing properties. Experimental
evidence obtained in cultured human cancer cells suggests that
a variety of natural phytochemicals from dietary and non-dietary
sources represent promising sources of chemotherapeutic agents
that can potentially target telomerase with few side effects
(reviewed in [242,297,305]). Regulation of telomerase activity
and/or expression, localization of speciﬁc components of the
telomerase protein–RNA complex or posttranslational modiﬁca-
tions by phytochemicals have been observed. Among the ﬁrst
phytochemicals reported to repress telomerase was the com-
pound berberine, leading to identiﬁcation of the more potent
anti-telomerase analogue FJ5002 [282], though this was not fur-
ther developed. Indicative of the complexities of understanding
the precise mechanism of action of natural products, tested phy-
tochemicals appear to disrupt different telomerase-associated
processes in cancer cells from different tissue sources [242]. Also, a
few studies have shown that certain phytochemicals can inhibit
or stimulate expression of telomerase components in different
cancer cells [242]. Because of the varied effects on telomerase, spe-
ciﬁc sets of phytochemicals could conceivably be used alone or
as complementary agents in combinational therapeutic strategies
with established protocols for the prevention and/or treatment of
human cancers. Examples of phytochemicals with demonstrated
bioactivity against telomerase include (a) isoprenoids – such as
perillyl alcohol, genistein, and ﬁsetin, (b) polyphenols – such as
curcumin, resveratrol, and EGCG, (c) indole-3-carbinol, and (d) sul-
foraphane (Table 1).
Among the isoprenoids, perillyl alcohol, a small, lipophilic prod-
uct of the plant mevalonate biosynthetic pathway [306–308],
suppresses the growth of tumor cells in culture as well as in
rodent models [309–313]. Perillyl alcohol acts on protein transla-
tion through modulation of mTOR signaling in cultured prostate
cancer cells [314] and in mice with intracranial gliomas [310].
Mechanistically, perillyl alcohol has been shown to disrupt com-
plex formation between mTOR and hTERT, causing p70 S6 kinase
(S6K), heat shock protein 90 (Hsp90), and hTERT to dissociate from
the regulatory-associated protein of mTOR (RAPTOR) [293,294].
Genistein – another isoprenoid found in soy and fava beans –
has independently been shown to down-regulate telomerase activ-
ity and attenuate 4E-BP1 phosphorylation, an indicator of mTOR
signaling [314–316]. Genistein down-regulates hTERT levels by
the inhibiting hTERT gene promoter activity in human prostate
cancer cells [315]. This study also showed that exposure to genis-
tein inhibited expression of the c-Myc, possibly attenuating its
transcriptional activation of the hTERT promoter; however, the
inhibitory effects of genistein on hTERT promoter activity likely
require the disruption of one or more factors in addition to c-
Myc. One contrasting study showed that genistein stimulated
hTERT expression in reproductive cancer cells by enhancing STAT3
activity [317], however, the biological context of this observa-
tion is not well understood. Consistent with the transcriptional
inhibitory effects of genistein, treatment of lung cancer cells with
the ethyl acetate fraction of ginger extracts concurrently down reg-
ulated hTERT and c-Myc expression, which resulted in a loss of
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Table  1
Therapeutic targeting by select phytochemicals.
Phytochemical Targets Current state of evidence
Perillyl alcohol mTOR [292–296,310,314]
Telomerase [292–296]
Ras-Erk [309,310]
Cell lines [292–296,310,311,314,368]
Animal models [307–311]
Clinical trials [369–372]
Curcumin mTOR [326,327,373,374]
Telomerase [322–325,375]
Akt [326,373]
Hsp90 [325]
NF-B [328,375]
JAK/STAT [328,376]
MAPK [328,329]
Cell lines [322–327,373,375,376]
Animal models [334,373–375]
Clinical trials [377–380]
Resveratrol mTOR [334,381]
Telomerase [332,333]
Akt [334,382]
MAPK [383,384]
Cell lines [332,333]
Animal models [334,381,384]
Clinical trials [385–387]
EGCG mTOR [335,388]
Telomerase[336–339]
PI3K[335,388]
NF-B [335,389]
JAK/STAT [335,390]
MAPK [335,391]
Cell lines [336–339,389,390,392,393]
Animal models [337,338,394]
Clinical trials [395–397]
Genistein mTOR [314,398]
Telomerase [315,316]
Akt [314]
Cell lines [314–316]
Clinical trials [399]
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PI3K/Akt [319,320]
elomerase activity [318]. Genistein also has a strong posttrans-
ational effect on telomerase compartmentalization in prostate
ancer cells where it caused down-regulation of the Akt depend-
nt phosphorylation of hTERT and thereby inhibited hTERT
ranslocation into the nucleus [315]. Another structurally similar
hytochemical, ﬁsetin, decreases phosphorylation of multiple pro-
eins within the Akt and mTOR pathway, including PI3K, mTOR, S6K
nd 4E-BP1 [319,320]. Furthermore, ﬁsetin has shown antitumor
fﬁcacy in Lewis mouse lung tumor models [321].
Among polyphenolic compounds, curcumin – a component
f the spice turmeric, has also been shown to inhibit telome-
ase directly and indirectly in human brain, breast, cervical, and
eukemic cell lines [322–325]. This phytochemical reduces mTOR
ignaling by inhibiting phosphorylation of S6K and 4E-BP1, and
isrupts the mTOR–RAPTOR interaction [326–328]. Like other phy-
ochemicals, curcumin has a range of pleiotropic effects and has
een reported to modulate the expression and/or activity of a range
f pro- and anti-apoptotic proteins as well as telomerase regulatory
actors such as c-Myc and the p53 family [324]. In addition to its
ffects on mTOR, curcumin modulates additional cellular pathways,
ncluding JAK-STAT, NF-B, and MAPK, that impact telomerase reg-
lation and cancer cell growth [328,329]. In breast cancer cells,
urcumin down-regulation of the levels of the NFkB transcription
actor has been proposed to attenuate hTERT expression [330]. In
ung cancer cells, curcumin stimulates the level of reactive oxygen
pecies, which triggers the proteasome degradation of the Sp1 tran-
cription factor leading to the loss of hTERT gene expression [331].
urcumin exposure was  also shown to stimulate the cytoplasmic
etention of hTERT protein by causing dissociation of hTERT from
ts chaperone p23 [325]. Resveratrol, another natural phenol pro-
uced in many plants including grapes, has been found to decrease
TERT protein levels and inhibit telomerase activity [332,333]. The
ombination of curcumin and resveratrol reduced cancer incidence
n PTEN knockout mice [334]. EGCG is similar to curcumin in that
t was found to modulate multiple oncogenic signaling pathways
uch as JAK/STAT, MAPK, and PI3K/Akt/mTOR [335]. EGCG down-
egulated telomerase activity in multiple carcinoma cell lines and
n mouse xenograft tumors [336–339].
Other phytochemicals with demonstrated telomerase regula-
ory properties include indole-3-carbinol, a naturally occurringCell lines [319,320]
Animal models [321]
hydrolysis product of glucobrassicin, and the dietary isothio-
cyanate, sulforaphane, both from cruciferous vegetables such as
broccoli and Brussels sprouts. Treatment of cultured breast cancer
cells with indole-3-carbinol induced cell cycle arrest and disrupted
combined estrogen receptor-alpha and Sp1-driven transcription of
the hTERT gene [340]. Chromatin immunoprecipitation analysis of
the endogenous hTERT promoter showed that indole-3-carbinol
inhibited binding of both estrogen receptor-alpha and Sp1 to a
composite estrogen response-Sp1 element in the hTERT promoter
[340]. Similar to curcumin, exposure to sulforaphane elevated
intracellular reactive oxygen species in hepatocellular carcinoma
cells and this process was functionally linked to the inhibition of
hTERT gene expression [341]. In hepatocellular carcinoma cells and
in breast cancer cells, sulforaphane suppressed Akt kinase activity,
which resulted in the loss of hTERT phosphorylation [341].
Candidate telomerase inhibitory natural products are not
restricted to phytochemicals. Axinelloside A, a sulphated
lipopolysaccharide isolated from the marine sponge Axinella
infundibula, is found to inhibit telomerase [342]. However, no
further studies in relation to telomerase have been reported
using this highly complex compound. Telomestatin is a natural
macrocyclic pentaoxazole isolated from Streptomyces anulatus that
inhibits telomerase activity and causes telomere shortening and
apoptosis in a range of cancer cell lines in vitro as well as leukemia
xenografts. Telomestatin also augments apoptosis induced by vari-
ous chemotherapeutic agents [343–346]. However, its puriﬁcation
is inefﬁcient and total synthesis is highly complex [347,348].
9. Therapeutic targeting of telomeres
Another plausible approach to the inhibition of telomere main-
tenance is to directly target telomeres, or to manipulate the
shelterin proteins that provide telomere secondary structure and
telomerase access (reviewed in [3]). One potential target that has
attracted considerable interest is tankyrase 1, a poly(ADP-ribose)
polymerase (PARP) family protein that modiﬁes the shelterin
protein TRF1 [349,350]. By modifying TRF1, tankyrase 1 causes
displacement of TRF1 from the telomere, thereby promoting telo-
mere unfolding and enabling telomerase to access and lengthen
the telomere. General PARP inhibitors have been shown to impede
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Table  2
Cross-validation of selected targets and agents.
Targets for replicative
immortality
Telomerase
(inhibit)
hTERT (inhibit) mTOR (inhibit) CDK4/6
(inhibit)
CDK1/2/5/9
(inhibit)
Akt (inhibit) PI3K (inhibit)
Other cancer hallmarksa
Genomic instability +/−
[400–402]c
+/−
[400–402]
0 −
[403]
+
[404,405]
+
[406–408]
+
[409]
Sustained proliferative
signaling
+
[410]
+
[411–413]
+
[414–416]
+
[417,418]
+
[419–421]
+
[415,422,423]
+
[424,425]
Tumor promoting
inﬂammation
+
[410]
+
[410]
+
[426,427]
+
[428]
+
[429,430]
+
[431,432]
+
[433,434]
Evasion of anti-growth
signaling
+
[258,276,435]
+
[258,276,435]
+/−
[436,437]
+
[438,439]
+
[440–442]
+
[443,444]
+
[445,446]
Resistance to apoptosis +
[447]
+
[448]
+
[449]
+
[450]
+
[451]
+
[452]
+
[452]
Dysregulated
metabolism
+
[453]
0 +
[454]
+
[455]
+
[456]
+
[457,458]
+
[459,460]
Immune system
evasion
0 0 +/−
[461]
0 0 +
[462]
+/−
[463,464]
Angiogenesis +
[465]
+
[465]
+
[466,467]
+
[468,469]
+
[470,471]
+
[466]
+
[466]
Tissue invasion and
metastasis
+
[472,473]
+
[472,473]
+
[474,475]
+/−
[476,477]
+
[478,479]
+
[480]
+
[475]
Tumor
microenvironment
+
[481]
+
[482]
+
[483]
+
[484]
−
[485,486]
+
[487,488]
+
[488,489]
Approaches GRN163L
(imetelstat)
Genistein Perillyl
alcohol
PD 0332991
(palbociclib)
SCH 727965
(dinacicilib)
Curcumin EGCG
(epigallocatechin-
3-gallate)
Other cancer hallmarksb
Genomic instability +/−
[490,491]
+/−
[492,493]
+
[494]
0 0 +
[495,496]
+/−
[497,498]
Sustained proliferative
signaling
0 +/−
[499,500]
+
[501,309]
+
[502]
+
[503]
+
[504,505]
+
[506,507]
Tumor promoting
inﬂammation
0 +/−
[508–510]
+
[309,511]
0 0 +
[512–514]
+
[515,516]
Evasion of anti-growth
signaling
+
[258]
+
[517–519]
+
[520]
+
[502,521]
+
[522]
+
[523,524]
+
[525,526]
Resistance to apoptosis +
[276]
+
[527,528]
+
[529,530]
+
[502,531]
+
[522,532]
+
[533,534]
+
[535,536]
Dysregulated
metabolism
0 +
[537]
+
[310]
0 0 +
[538]
+
[539,540]
Immune system
evasion
0  +
[541]
0 0 0 +
[542,543]
+/−
[544–546]
Angiogenesis 0 +
[547–549]
+
[550]
0 0 +
[551]
+
[552,553]
Tissue invasion and
metastasis
0 +/−
[554–556]
+
[310]
−
[476]
+
[503]
+
[557,558]
+
[559–561]
Tumor
microenvironment
+
[562]
+
[563]
+
[550]
0 +
[564]
+
[565,566]
+
[567]
a Potential consequences of targeting indicated protein complexes involved in the maintenance of replicative immortality on other hallmarks of cancer: +, inhibition of
indicated target has beneﬁcial consequences for hallmark; −, inhibition of indicated target exacerbates hallmark; +/−,  inhibition of indicated target has both positive and
negative effects on hallmark; 0, no published evidence of any effect on hallmark.
b Potential consequences of the use of selected agents targeting pathways involved in the maintenance of replicative immortality on other hallmarks of cancer: +, indicated
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c Numbers in brackets refer to references containing evidence for potential conse
elomere length maintenance and augment the activity of the
elomerase inhibitor MTS-312 in experimental systems [349]. Com-
ounds that speciﬁcally inhibit the PARP activity of tankyrase 1 are
ow available for experimental purposes and provide a starting
oint for the development of tankyrase inhibitors for advancement
o clinical trials [351]. Since tankyrase 1 is known to modulate the
ctivity of pathways that that contribute to cancer cell proliferation
ndependently of telomerase (e.g., the WNT/-catenin pathway),
his area of investigation holds considerable promise.
There is a body of evidence that suggests that the 3′ G-rich
ingle stranded overhang of the telomere forms a G-quadruplex
tructure that is not accessible to telomerase [352,353]. G-
uadruplex stabilizers therefore present a possible alternate means
f manipulating telomere maintenance in cancer cells. Molecules
hat stabilize G-quadruplexes and have been tested for telo-
ere effects include porphyrins (TMPyP4), perylenes (PIPER),k; +/−, indicated agent has both positive and negative effects on hallmark; 0, no
ces listed.
acridine derivatives (BRACO19, RHPS4), quinoline-substituted tri-
azines and natural products, such as telomestatin [354–358]. At
non-toxic concentrations, these compounds diminished telome-
rase enzyme activity, induced telomere shortening and arrested
tumor cell proliferation after a lag period [358,359]. Decreased
tumor growth rates were also demonstrated in mice xenografted
with leukemia cells [343,344,360]. G-quadruplex stabilizing agents
may  also facilitate the action of standard chemotherapeu-
tic agents and molecular targeted treatments [356,359]. For
instance, telomestatin was shown to enhance the sensitivity of
acute myeloid leukemia cells to danunorubicin and cytosine-
arabinoside, and was effectively combined with the tyrosine kinase
inhibitor imatinib to kill chronic myeloid leukemia progenitor
cells [247,344,361]. These results clearly illustrate the potential
of G-quadruplex stabilizing agents for the treatment of malig-
nancy.
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0. Other potential therapeutic targets
Because of a lack of deﬁnitive molecular criteria, there is
urrently no consensus regarding properties that contribute to efﬁ-
ient senescence induction. Conceivably, any compound or agent
hat causes DNA damage or otherwise alters replication may  cause
enescence at doses that are not cytotoxic. Additionally, agents that
timulate differentiation pathways (such as retinoic acid [362]),
ay  induce senescence in cancer cells that are not able to respond
ppropriately; this phenomenon which so far has received little
ttention, can potentially be the basis of truly non-toxic alterna-
ive therapies. The therapeutic utility of speciﬁc compounds will
epend on standard factors such as whether activation is required,
ptake and retention, as well as detoxiﬁcation and repair capac-
ties of the target cells versus those of normal cells providing
ital functions. Beyond these considerations, however, the speciﬁc
enetic and epigenetic traits of prospective target cells are likely
o have large inﬂuences on senescence susceptibility and stability.
or example, while conventional genotoxic chemotherapy is often
ffective at inducing senescence when used at maximally tolerated
oses, tumor resistance and recurrences remain signiﬁcant clin-
cal problems, particularly in patients whose tumors retain intact
53 responses [363,364]. When treated with genotoxins, wild-type
53 tumors show induction of p21 and SA-gal, but not p16, and
umor growth often recurs after treatment [364]. Tumor recurrence
ight be signiﬁcantly impeded in these cases through the concur-
ent administration of CDK inhibitors that circumvent defects in
he p16/pRB pathway, causing the activation of RB-family depend-
nt heterochromatin formation at E2F-dependent promoters, and
tabilization of the senescent phenotype in target cells. Similarly,
elomere and telomerase targeting therapies might be improved by
he inclusion of agents that induce oxidative stress to discourage
he selective outgrowth of ALT+ cells [240].
1. Opportunities for senescence drug discovery
In terms of drug discovery, components of the various senes-
ence pathways represent potential targets. To determine whether
r not accelerated senescence is a desirable clinical outcome of can-
er therapy, it will be necessary to develop efﬁcient and speciﬁc
pproaches to modulate relevant pathways in order to activate the
esponse in a predictable fashion. Thus, ‘proof of concept’ and tar-
et validation are necessary before senescence will be seriously
onsidered as an area for widespread commercial drug discovery.
rogress in this area has been made through the application of cell-
ased screening approaches [365]. Cell-based assays offer potential
o identify partially validated hits with improved lead-like quali-
ies at the earliest stages of discovery and offer a number of critical
dvantages over conventional biochemical screening assays. Puriﬁ-
ation of the target protein in a functional conformation is not
equired. Instead, the key requirement is a measurable marker of
ndogenous target inhibition such as a change in reporter activity,
rotein phosphorylation, or cell morphology. Importantly, cell-
ased assays may  also discriminate between different drug effects,
uch as antagonism versus agonism, and identify hits that inter-
ct with different target conformations that may  be present in
 physiological setting. The characteristic morphological changes
ssociated with cell senescence including cell enlargement and SA-
Gal activity are suitable for cell based screening approaches using
igh content automated imaging. The validity of this approach
as recently been demonstrated in both normal and cancer cell-
ased screening strategies using siRNA or small molecule libraries
o identify compounds that modulate senescence and targets for
urther validation [366,367]. Interestingly, in these studies, senes-
ence occurs in a matter of days post treatment, an advantage over
he longer lag time generally associated with telomerase inhibition. Biology 35 (2015) S104–S128 S117
Thus senescence is already beginning to show great promise as
an endpoint for drug targeting. Cell-based senescence models and
assays have contributed considerably to advancing new approaches
to drug development. Importantly, a number of agents already
used in the management of human cancers also show associations
with senescence phenotypes, opening up opportunities for drug
re-positioning [80,365]. However, the key questions as to which
patient group will beneﬁt from such agents and clinical trial design
are still open to debate and likely to revolve around the speciﬁc
target in question.
12. Cross-validation
Given the heterogeneity present in most cancers, complete
arrest/eradication of the various subpopulations of cells in any
given cancer will likely require simultaneous targeting of several
molecules and mechanisms that contribute to the malignant phe-
notype. It is therefore important to anticipate complementary as
well as antagonistic effects on different cancer hallmarks that might
be achieved using agents directed against speciﬁc targets. Accord-
ingly, a literature search has been conducted by a “cross-validation”
team to identify potential consequences of the use of selected
agents targeting protein complexes involved in the maintenance of
replicative immortality on other hallmarks of cancer. The results of
this survey are listed in Table 2. The table indicates that not all inter-
actions are favorable; some agents efﬁcacious against replicative
immortality may  exacerbate other hallmarks (e.g., genetic instabil-
ity), and their utility may  be context-dependent.
13. Conclusions
Developing optimized and truly holistic cancer prevention and
treatment regimens will likely incorporate strategies that target
replicative immortality. The chief advantage to be gained by the
use of these senescence-inducing regimens is elimination of tumor
repopulating ability with reduced collateral damage compared to
conventional cytotoxic regimens. There are certain questions and
risks associated with this strategy that must be addressed before
its wholesale adoption in clinical settings. In the case of telo-
mere and telomerase based strategies, replicative senescence may
occur more readily in cancer cells bearing short telomeres than
in vital normal cells with long telomeres, but telomere lengths in
cancer cells may still be long enough to permit sufﬁcient popu-
lation doublings for invasion and metastases to occur. Moreover,
telomere dysfunction promotes the development of chromosomal
instability, which in turn can generate mutations that enable cells
to become drug resistant and/or activate ALT mechanisms for
telomere maintenance and/or become more malignant. High pri-
ority should be given to further research into the determinants of
senescence stability, as the implications of delayed cell cycle
re-entry, permanent cytostasis, or eventual clearance may  be pro-
foundly different. Lower doses of genotoxic drugs needed to induce
senescence may  reduce collateral damage, but allow establishment
of dormancy by resistant cells. Conversely, since it is almost impos-
sible to kill all the cells in a tumor even at the highest tolerated
doses of chemotherapy, addition of a complementary agent that
induces or enhances stable senescence in the cancer cells that man-
age to retain viability might additively or synergistically increase
therapeutic efﬁcacy. The microenvironmental and systemic effects
of senescent cells also need further clariﬁcation. While senescent
cells have been shown to secrete proteins that aid in their own
clearance and tissue repair, persistent senescent cells can dis-
rupt niches, causing the depletion of healthy stem cells, and can
promote aging and cancerous phenotypes in surrounding tissues.
Given that some senescence-associated secretory phenotypes can
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